Press Release

August 14, 2018
Stem Cell & Device Laboratory Co., Ltd.
http://scad-kyoto.com/

SCAD exhibits and presents at 5th TERMIS World Congress 2018

SCAD will exhibit and present at the 5th TERMIS (Tissue Engineering and Regenerative Medicine International Society) World Congress 2018 from September 4-7 in Kyoto, Japan. This event is jointly organized with the Japanese Society for Regenerative Medicine (JSRM) and it will bring together researchers and practitioners from the fields of cell engineering, stem cell biology, and regenerative medicine. Please join us to learn about SCAD-MT™ cardiomyocyte, our initial 3D cell device, and SCAD-MT™ neuron, which is currently under development. Anyone interested in 3D cell culturing and its use for the evaluation of drug responses are welcome to come to our booth and to participate in the luncheon seminar (details below).

General information
Date: September 5-7, 2018
Place: Kyoto International Conference Center (http://www.icckyoto.or.jp/)
Booth: Inside the event hall’s central exhibition space (booth number 11c)
Luncheon seminar:
  Title: SCAD-MT™ cardiomyocyte, 3D-cell device with aligned and multilayered myocardial tissue derived from iPS cells for cardiotoxicity testing
  Date and time: September 6, 2018 (Thu), 11:45-12:35
  Place: Room 2 (Annex Hall 1)
  For more information on the luncheon seminar, please click here to download the flyer.

We will strive towards the realization of “a new society created by stem cells” through the rapid and efficient translation of our R&D efforts into cell product innovations that fulfill the requirements of our customers throughout the world. We appreciate your continued support in the future.

About SCAD
SCAD is an innovative biotech company offering cell product and service innovations that accelerate drug discovery and development through the convergence of nanotechnology, micro-engineering, and stem cell technologies. By harnessing the leading-edge technologies of Prof. Norio Nakatsuji’s group at Kyoto University, SCAD is committed to the development, manufacturing and commercialization of the next generation of cells and cell devices based on iPS cell technologies. SCAD’s proprietary technologies in nanofiber-based cell culturing allow the creation of 3D, multilayered microtissues that closely recapitulate native tissues through increasing levels of maturity and functionality. Our initial offering is centered on the SCAD-MT™ cardiomyocyte, a myocardial microtissue, but other types of tissues are expected to come to market soon. As a company, we strive to contribute to the wellbeing of society by enabling the faster delivery of efficacious and safe medicines to patients.

For more information
Stem Cell & Device Laboratory, Inc. (SCAD)
Management Section: Mrs. Sonoko Chiaki
TEL: 075-744-1114; E-mail: scad.info@scad-kyoto.com